That $930M drug Alex­ion bought to pair with Soliris, Ul­tomiris? As­traZeneca says it just aced a PhI­II test

Back in 2019, Alex­ion paid $930 mil­lion to snap up Achillion and dan­i­co­pan, its promis­ing com­pan­ion drug to Soliris. Three years lat­er, Alex­ion it­self be­came a sub­sidiary of As­traZeneca — which is tak­ing the hon­ors Fri­day morn­ing to an­nounce an in­ter­im Phase III suc­cess.

The drug met its pri­ma­ry end­point of change in he­mo­glo­bin among pa­tients with parox­ys­mal noc­tur­nal he­mo­glo­bin­uria who ex­pe­ri­ence clin­i­cal­ly sig­nif­i­cant ex­travas­cu­lar he­mol­y­sis, when giv­en on top of ei­ther Soliris or the fol­low-on Ul­tomiris.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER